There are currently 1879 clinical trials in Philadelphia, Pennsylvania looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Pennsylvania, Children's Hospital of Philadelphia, Fox Chase Cancer Center and Thomas Jefferson University. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
NCT04649242
Recruiting
The purpose of this study is to test the safety and efficacy of BHV-3000 versus placebo in the acute treatment of moderate or severe migraine in children and adolescents.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
07/07/2025
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Pediatric Migraine
Register for Updates
TSC Biosample Repository and Natural History Database
NCT05676099
Recruiting
The TSC Biosample Repository collects and stores samples of blood, DNA, and tissues that scientists can request to use in their research. The samples we collect are all linked to clinical data in the TSC Natural History Database. The TSC Natural History Database captures clinical data to document the impact of the disease on a person's health over his or her lifetime. This data may be collected retrospectively or prospectively.
Gender:
ALL
Ages:
All
Trial Updated:
07/07/2025
Locations: University of Pennsylvania Medical Center, Philadelphia, Pennsylvania
Conditions: Tuberous Sclerosis, Lymphangioleiomyomatosis
Register for Updates
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
NCT05651932
Recruiting
A Phase I study to evaluate the safety of a novel, orally available, selective, and potent small molecule inhibitor of the histone lysine methyl transferase MMSET (also known as NSD2/WHSC1) to prevent the dimethylation of H3K36 in adult patients with relapsed or refractory multiple myeloma (RRMM).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/07/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Multiple Myeloma, Myeloma, Myeloma Multiple
Register for Updates
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
NCT05878717
Recruiting
This study investigates the efficacy and safety of belimumab compared to placebo, in addition to standard therapy, for the treatment of participants with systemic sclerosis associated interstitial lung disease (SSc-ILD). The study will evaluate the effect of belimumab treatment on lung function as well as on extra-pulmonary disease manifestations, including skin thickening and general symptoms, such as fatigue, that impact quality of life (QoL).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/07/2025
Locations: GSK Investigational Site, Philadelphia, Pennsylvania +1 locations
Conditions: Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic
Register for Updates
A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
NCT06641466
Recruiting
The purpose of this study is to evaluate the efficacy and safety of rimegepant when administered during the peri-menstrual period (PMP) for intermittent prevention of migraine in women who experience menstrual migraine attacks.
Gender:
FEMALE
Ages:
Between 18 years and 45 years
Trial Updated:
07/07/2025
Locations: Clinical Research of Philadelphia, Philadelphia, Pennsylvania
Conditions: Menstrual Migraine
Register for Updates
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
NCT06890598
Recruiting
The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if olomorasib in combination with durvalumab is more effective than the durvalumab and placebo combination in part B in participants with unresectable KRAS G12C-mutant non-small cell lung cancer. The study may last up to 3 years for each participant.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/07/2025
Locations: Thomas Jefferson University, Sidney Kimmel Cancer Center - Clinical Trials Office, Philadelphia, Pennsylvania
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)
NCT06635824
Recruiting
This is a multicenter, randomized, open-label, international, Phase 3 trial to evaluate the efficacy and safety of acasunlimab in combination with pembrolizumab versus docetaxel (standard of care) in participants with programmed death ligand 1 (PD-L1)-positive metastatic non-small cell lung cancer (NSCLC) who have been treated with programmed cell death protein 1 (PD-1)/PD-L1 inhibitor and platinum-containing chemotherapy, administered either in combination or sequentially in the metastatic sett... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/07/2025
Locations: University of Pennsylvania Health System, Philadelphia, Pennsylvania
Conditions: PD-L1-positive Metastatic NSCLC
Register for Updates
Aspirin Dose Escalation for the Prevention of Recurrent Preterm Delivery Trial
NCT06980025
Recruiting
This is a phase-III multi-center double-blind randomized clinical trial of 1,800 individuals with a history of prior preterm birth at less than 35 weeks gestation who are randomized to either 162 mg aspirin or 81 mg aspirin daily. The study drug will be initiated between 10 and 15 weeks gestation and continued through 36 weeks, 6 days gestation. The primary endpoint is recurrent preterm delivery or fetal death prior to 35 weeks, 0 days gestation.
Gender:
FEMALE
Ages:
14 years and above
Trial Updated:
07/07/2025
Locations: Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Preterm Delivery, Obstetrical Complications
Register for Updates
Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN
NCT05755386
Recruiting
This study is designed as a multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in idiopathic immune complex mediated membranoproliferative glomerulonephritis.
Gender:
ALL
Ages:
Between 12 years and 60 years
Trial Updated:
07/07/2025
Locations: Univ of Pennsylvania Medical Center, Philadelphia, Pennsylvania
Conditions: IC-MPGN
Register for Updates
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
NCT06653153
Recruiting
The purpose of this study is to measure the difference in time to developing or worsening memory, thinking, or functional problems due to Alzheimer's disease occurring in participants receiving study drug compared to placebo. Participation could last up to 255 weeks including screening, a double-blind treatment period, and a double-blind observation period. In addition, eligible participants who receive placebo during the double-blind treatment period may choose to extend their study participat... Read More
Gender:
ALL
Ages:
Between 55 years and 80 years
Trial Updated:
07/07/2025
Locations: Clinical Research of Philadelphia, Philadelphia, Pennsylvania
Conditions: Alzheimer's Disease
Register for Updates
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer
NCT05999994
Recruiting
The main purpose of the master is to help the research sites and sponsor carry out several clinical trials more efficiently by providing a common research protocol. Individual clinical trials under this master protocol define drug/disease-specific research goals and activities to test them. New studies will be added as new drugs emerge against different cancers. Participation in the trial will depend on how long the benefit lasts.
Gender:
ALL
Ages:
Between 1 year and 39 years
Trial Updated:
07/07/2025
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Neoplasms, Child, Adolescent
Register for Updates
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
NCT06739122
Recruiting
The main purpose of this study is to evaluate additional dosing options for dulaglutide in pediatric participants with Type 2 Diabetes. Participation in this study will last about 8 months.
Gender:
ALL
Ages:
Between 10 years and 17 years
Trial Updated:
07/07/2025
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Type 2 Diabetes
Register for Updates